Utility of CART22-65s and huCART19 in R/R ALL: Noelle V. Frey, MD, MSCE
The associate professor from Perelman School of Medicine, University of Pennsylvania, discussed co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Noelle V. Frey, MD, MSCE, Constance and Sankey Williams Associate Professor, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, to learn more about the utility of co-administered CART22-65s and huCART19 in relapsed/refractory acute lymphoblastic leukemia (ALL).
Data from a phase 1 study on the combination were presented at the 63rd Annual American Society of Hematology (ASH) Meeting, December 11-14, 2021.
Investigators found that 2 of the 13 patients infused with CART22-65s and huCART19 developed toxicity before the 28-day assessment, leading 1 to die from therapy-related complications, and the other to develop rapidly progressive disease. However, the 11 patients who were evaluable at the 1-month time point allachieved complete remissions that were minimal residual disease negative, Frey explained.
Overall, the co-administered products were well tolerated; cytokine release syndrome (CRS) and neurotoxicity were observed but manageable, Frey said. Hemophagocytic lymphohistiocytosis-like syndrome (HLH) was a unique toxicity attributed to CART22-65s. HLH is clinically distinct from traditional CRS and has been noted in CART22-65s products before, Frey adds. The toxicity was mitigated in the patient who developed HLH, and they were able to continue with a sustained remission, Frey concludes.
Considerations for Administering Hemoglobinopathy Gene Therapies From a Pharmacist’s Perspective
April 20th 2024Alexis Kuhn, PharmD, BCOP, a pediatric oncology pharmacist at Mayo Clinic, discussed the incorporation of the recently FDA-approved gene therapies for SCD and TDT into the work of pharmacists.
